Cassava Sciences, Inc.

Contributing Author

Recent Articles by Cassava Sciences, Inc.

Jan-13	Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease SAVA GlobeNewswire
Dec-23	Cassava Announces Agreement to Settle Securities Class Action Litigation SAVA -7.56% GlobeNewswire
Nov-12	Cassava Reports Q3 2025 Financials Results and Provides Business Update SAVA GlobeNewswire
Oct-22	Cassava Sciences Appoints Dawn C. Bir to the Board of Directors SAVA -7.04% GlobeNewswire
Aug-25	Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference SAVA GlobeNewswire
Aug-14	Cassava Reports Q2 2025 Financials Results and Provides Business Update SAVA +5.70% GlobeNewswire
Aug-07	Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer SAVA -6.41% GlobeNewswire
Aug-04	Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy SAVA +8.02% GlobeNewswire
Jun-30	Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting SAVA GlobeNewswire
May-08	Cassava Reports Q1 2025 Financials Results, Provides Business Update SAVA +8.97% GlobeNewswire